Sucralose Effects on Glucose Metabolism and Gut Microbiota
NCT ID: NCT02650947
Last Updated: 2017-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2016-01-31
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Long-term consumption of sucralose may effect glucose metabolism, incretin hormone secretion and gut microbiota in healthy adults.
2. Long-term consumption of sucralose may alter food behaviour in healthy adults.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1
NCT06094894
Sucralose and Glucose Metabolism in Young Healthy Adults
NCT07194772
Effect of Non-nutritive Sweeteners of High Sugar Sweetened Beverages on Metabolic Health and Gut Microbiome
NCT03259685
Sucralose, Stevia, Gut Microbiome and Glucose Metabolism
NCT02800707
Effects of Sucralose in Insulin Sensitivity
NCT04182464
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sucralose
Subjects in this group ate capsule filled with sucralose 200 mg for 4 weeks (week 1-4) and measured oral glucose tolerance test (OGTT), acute insulin response (AIR), and gut microbe examination at week 4.
Sucralose
Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
Placebo
Subjects ate empty capsule (placebo) for 4 weeks (week 1-4) and measured OGTT, AIR, and gut microbe examination at week 4.
Placebo
Consumption of empty capsule everyday for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sucralose
Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
Placebo
Consumption of empty capsule everyday for 4 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal oral glucose tolerance test
* Agree to participate by written informed consent
Exclusion Criteria
* History of diabetes mellitus or prediabetes (impaired fasting glucose and/or glucose tolerance test)
* Malabsorption problem
* Regular consumption of nonnutritive sweeteners
* Liver impairment (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 3-folds upper normal limit)
* Renal impairment (serum creatinine \>1.5 mg/dL)
* Use of medications affecting glucose level such as glucocorticoid, estrogen, androgen
* Pregnant and lactating woman
* Smoking within 6 months
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Endocrine Society of Thailand
OTHER
Ramathibodi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chutintorn Sriphrapradang
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chutintorn Sriphrapradang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Ramathibodi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-58-16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.